Differing formulations and ratios of the subjects’ medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.
Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.
The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.
Although the study demonstrated a lower relapse rate among patients with MS who supplemented their diet with vitamin D, the analysis did not reach statistical significance.
The FDA’s decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.
Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.
A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.
A cross-sectional study aimed to assess the effect of smoking and alcohol consumption along with the interactions they have on the clinical course of multiple sclerosis.
Participants who were treated with both doses of fingolimod experienced less overall progression of disability than those receiving placebo.
Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.
